Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors.
Anna SerefkoDepartment of Clinical Pharmacy and Pharmaceutical Care, Medical University of Lublin, 1 Chodźki Street, PL 20-093 Lublin, Poland.ORCID 0000-0002-5732-8950
Joanna Lachowicz-RadulskaDepartment of Clinical Pharmacy and Pharmaceutical Care, Medical University of Lublin, 1 Chodźki Street, PL 20-093 Lublin, Poland.ORCID 0000-0002-1722-6255
Aleksandra SzopaDepartment of Clinical Pharmacy and Pharmaceutical Care, Medical University of Lublin, 1 Chodźki Street, PL 20-093 Lublin, Poland.ORCID 0000-0002-7756-2904
Mariola HerbetChair and Department of Toxicology, Medical University of Lublin, 8 Chodźki Street, PL 20-093 Lublin, Poland.ORCID 0000-0001-8975-8093
Agnieszka CzylkowskaInstitute of General and Ecological Chemistry, Faculty of Chemistry, Lodz University of Technology, 116 Żeromskiego, PL 90-924 Lodz, Poland.ORCID 0000-0001-7157-5408
Katarzyna IgnatiukStudent Scientific Club, Department of Clinical Pharmacy and Pharmaceutical Care, Medical University of Lublin, 1 Chodźki Street, PL 20-093 Lublin, Poland.
Anna DołotoStudent Scientific Club, Chair and Department of Toxicology, Medical University of Lublin, 8 Chodźki Street, PL 20-093 Lublin, Poland.
Bernadeta SzewczykDepartment of Neurobiology, Maj Institute of Pharmacology Polish Academy of Sciences, 12 Smętna Street, PL 31-343 Krakow, Poland.ORCID 0000-0002-6863-7951
Sylwia WośkoLaboratory of Preclinical Testing, Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, 1 Chodźki Street, PL 20-093 Lublin, Poland.
Andrzej WróbelSecond Department of Gynecology, Medical University of Lublin, 8 Jaczewskiego Street, PL 20-090 Lublin, Poland.ORCID 0000-0002-5772-0573
Jarosław SzponarClinical Department of Toxicology and Cardiology, Stefan Wyszynski Regional Specialist Hospital in Lublin, 100 Al. Kraśnicka, PL 20-550 Lublin, Poland.ORCID 0000-0001-9915-0719
Piotr WlaźDepartment of Animal Physiology and Pharmacology, Institute of Biological Sciences, Maria Curie-Skłodowska University, 19 Akademicka, PL 20-033 Lublin, Poland.ORCID 0000-0002-5389-0241
Piotr SkałeckiDepartment of Commodity Science and Processing of Raw Animal Materials, University of Life Sciences, 13 Akademicka Street, PL 20-950 Lublin, Poland.ORCID 0000-0001-9383-1863
Jan WróbelMedical Faculty, Medical University of Lublin, 1 Al. Racławickie, PL 20-059 Lublin, Poland.
Weronika SłotwińskaMedical Faculty, Medical University of Lublin, 1 Al. Racławickie, PL 20-059 Lublin, Poland.
Ewa PoleszakLaboratory of Preclinical Testing, Chair and Department of Applied and Social Pharmacy, Medical University of Lublin, 1 Chodźki Street, PL 20-093 Lublin, Poland.ORCID 0000-0003-4359-3953
Funding
Medical University of Lublin DS48
6 · The paper itself
Abstract
The objective of this study was to assess the antidepressant efficacy of a novel imipramine-magnesium (IMI-Mg) complex in comparison to the administration of imipramine and magnesium individually. The study utilized adult male albino Swiss mice. Behavioral assessments were conducted using the forced swim test (FST) and the tail suspension test (TST). A locomotor activity test was conducted to exclude false positive results in the FST and TST. Moreover, the study assessed oxidative stress levels in the mice subjected to acute environmental stress by measuring glutathione peroxidase, glutathione reductase, total oxidant status, and total antioxidant status. The administration of the IMI-Mg complex at doses of 5, 10, and 20 mg/kg resulted in a reduction in immobility time in both behavioral tests, thereby indicating the antidepressant-like potential of the tested complex, which was similar to the one observed after the administration of these two compounds as separate drug forms. The efficacy of the novel IMI-Mg complex represents a significant advancement and provides a foundation for future research. This innovative agent has the potential to enhance the safety profile of the therapy, streamline the treatment protocol, improve patient satisfaction, and promote adherence to the therapeutic regimen.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Novel Imipramine-Magnesium Complex Exerts Antidepressant-like Activity in Mice Subjected to the Forced Swim Test and the Tail Suspension Test. · full record | OpenQuestion